Evonik increases prices of pharmaceutical amino acids

Effective immediately, Evonik Industries is increasing the prices of its pharmaceutical amino acids. The increase, of between 10 and 15 percent depending on the amino acid and its quality, applies globally to all new orders and new supply agreements. The price increase is a result of the increased costs of raw materials and energy.

Evonik’s French subsidiary Rexim S.A.S. having production sites in Ham, France, and Nanning, China, is the world's third-largest supplier of amino acids and amino acid derivatives in pharmaceutical quality. These are used in the pharmaceutical industry for IV solutions and production of pharmaceutical active ingredients, such as those used to treat high blood pressure and diabetes, as well as in the cosmetics and food industries.